Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

Jan 28, 2011

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.

Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Ways to Make the Move

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

Fire at Russian Pathogen Lab

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Proteins From the Past

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

PNAS Studies Look at Diabetes Susceptibility, S. Aureus Subpopulations, More

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.

Featured White Papers

Delivering Precision Health: the Role of Molecular Diagnostics

BlueBee Data Security & Compliance

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Sep

18

Featured Webinar

Highly Sensitive Structural Variant Detection for Medical Genetics: A Comparison to the Standard of Care

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Oct

03

Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct

10

Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct

21

Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology.

Menu